---
{"dg-publish":true,"permalink":"/USMLE/Biochemistry/De novo pyrimidine and purine synthesis/","tags":["t1"]}
---

# Purine synthesis
![Pasted image 20231106152534.png](/img/user/appendix/Pasted%20image%2020231106152534.png)![De Novo Purine Synthesis - OG copy.png](/img/user/appendix/De%20Novo%20Purine%20Synthesis%20-%20OG%20copy.png)
# Pyrimidine synthesis
![Pasted image 20230912144319.png](/img/user/appendix/Pasted%20image%2020230912144319.png)
![Pasted image 20230910173723.png](/img/user/appendix/Pasted%20image%2020230910173723.png)
# Folate acid pathway
---
## **Folate Pathway: The Basics**

<span style="background:rgba(240, 200, 0, 0.2)">Folate (Vitamin B9) is converted to **Tetrahydrofolate (THF)**</span>, an essential coenzyme for:

1. **Purine synthesis** (Adenine, Guanine)
2. **Thymidine synthesis** (via N5,N10-methylene THF and thymidylate synthase)
3. Amino acid metabolism
## **Key Enzymes & Inhibitors:**

1. Dihydropteroate Synthase (Bacteria only)
	* Drug: Sulfonamides (e.g., Sulfamethoxazole - SMX)
		* MoA: PABA analogs; block bacterial folic acid synthesis.
		* Use: UTIs, PJP (often with Trimethoprim).
		* AEs: Hypersensitivity (SJS), photosensitivity, crystalluria, G6PD hemolysis, kernicterus.
2. Dihydrofolate Reductase (DHFR)
	* Drug: Trimethoprim (TMP) <span style="background:rgba(240, 200, 0, 0.2)">(Primarily bacterial DHFR)</span>
		* MoA: Inhibits bacterial DHFR ⟹ $\downarrow$THF.
		* Use: UTIs, PJP (synergistic with SMX = TMP-SMX/Co-trimoxazole).
		* AEs: Megaloblastic anemia, leukopenia, hyperkalemia. (Leucovorin can reduce bone marrow effects).
	* Drug: Methotrexate (MTX) <span style="background:rgba(240, 200, 0, 0.2)">(Human DHFR)</span>
		* MoA: Inhibits human DHFR ⟹ $\downarrow$THF ⟹ $\downarrow$DNA/RNA synthesis.
		* Use: Cancer, rheumatoid arthritis, psoriasis, ectopic pregnancy, immunosuppression.
		* AEs: Myelosuppression (dose-limiting), mucositis, hepatotoxicity, pulmonary fibrosis, nephrotoxicity, teratogenic.
		* Leucovorin (Folinic Acid) Rescue: Bypasses DHFR block in normal cells to reduce MTX toxicity.
			* <span style="background:rgba(240, 200, 0, 0.2)">Leucovorin is 5-formyl-tetrahydrofolate. This means its core pteridine ring structure is already in the fully reduced (tetrahydro) state, the same state that DHFR aims to achieve.</span>
	* Drug: Pyrimethamine (Protozoal DHFR)
		* MoA: Inhibits protozoal DHFR.
		* Use: Toxoplasmosis (with sulfadiazine), malaria.
		* AEs: Megaloblastic anemia. (Leucovorin can reduce bone marrow effects).
3. Thymidylate Synthase (Requires N5,N10-methylene THF from folate pathway)
	* Drug: 5-Fluorouracil (5-FU)
		* MoA: Pyrimidine analog; active metabolite FdUMP forms a complex with thymidylate synthase and N5,N10-methylene THF, inhibiting dTMP ("thymineless death").
		* Use: Solid tumors (e.g., colorectal, breast, pancreatic).
		* AEs: Myelosuppression, mucositis/diarrhea, hand-foot syndrome, photosensitivity.
		* <span style="background:rgba(240, 200, 0, 0.2)">Leucovorin (Folinic Acid) Potentiation: Enhances 5-FU efficacy by stabilizing the inhibitory complex (different role than with MTX).</span>
		* Note: DPD deficiency increases 5-FU toxicity.


| **Drug**           | **Target Enzyme/Process**                                       | **Primary Use(s)**                            | **Key Adverse Effects**                                          | **Leucovorin Interaction**            |
| ------------------ | --------------------------------------------------------------- | --------------------------------------------- | ---------------------------------------------------------------- | ------------------------------------- |
| **Sulfonamides**   | Bacterial Dihydropteroate Synthase                              | UTIs, PJP (bacterial infections)              | Hypersensitivity, photosensitivity, crystalluria, G6PD hemolysis | N/A                                   |
| **Trimethoprim**   | Bacterial Dihydrofolate Reductase (DHFR)                        | UTIs, PJP (bacterial infections, with SMX)    | Megaloblastic anemia, leukopenia, hyperkalemia                   | Rescue (bone marrow)                  |
| **Methotrexate**   | Human Dihydrofolate Reductase (DHFR)                            | Cancer, autoimmune disease, ectopic pregnancy | **Myelosuppression**, mucositis, hepatotoxicity, teratogenic     | **Rescue** (reduces toxicity)         |
| **Pyrimethamine**  | Protozoal Dihydrofolate Reductase (DHFR)                        | Toxoplasmosis, malaria                        | Megaloblastic anemia                                             | Rescue (bone marrow)                  |
| **5-Fluorouracil** | Thymidylate Synthase (via FdUMP & N5,N10-methylene THF complex) | Solid tumors (e.g., colorectal cancer)        | **Myelosuppression**, mucositis, diarrhea, hand-foot syndrome    | **Potentiation** (increases efficacy) |

![L28055.png](/img/user/appendix/L28055.png)![L25906.png](/img/user/appendix/L25906.png)
<span style="background:rgba(240, 200, 0, 0.2)">Para-aminobenzoic acid (PABA) is a folic acid precursor in prokaryotes.</span>  <span style="background:rgba(240, 200, 0, 0.2)">Sulfonamide</span> antibiotics are chemical analogues of PABA that inhibit the enzyme dihydropteroate synthetase, preventing bacterial conversion of PABA to folic acid.  <span style="background:rgba(240, 200, 0, 0.2)">Humans lack the ability to convert PABA to folic acid and require dietary folate.</span>
![highresdefault_L32115.jpg](/img/user/appendix/highresdefault_L32115.jpg)
The enzyme<span style="background:rgba(240, 200, 0, 0.2)"> thymidylate synthase</span> is responsible for <span style="background:rgba(240, 200, 0, 0.2)">converting deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP).</span>  Although most enzymes involved in one-carbon metabolism maintain folate in its active tetrahydrofolate form, thymidylate synthase is unique in that it oxidizes 5,10-methylenetetrahydrofolate to dihydrofolate.  <span style="background:rgba(240, 200, 0, 0.2)">This makes de novo thymidine synthesis particularly susceptible to folate-deficient conditions because tetrahydrofolate must be continuously regenerated by dihydrofolate reductase.</span>
